tradingkey.logo

CVRx Inc

CVRX
7.820USD
-0.210-2.62%
收盘 12/22, 16:00美东报价延迟15分钟
204.83M总市值
亏损市盈率 TTM

CVRx Inc

7.820
-0.210-2.62%

关于 CVRx Inc 公司

CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.

CVRx Inc简介

公司代码CVRX
公司名称CVRx Inc
上市日期Jun 30, 2021
CEOHykes (Kevin)
员工数量206
证券类型Ordinary Share
年结日Jun 30
公司地址9201 West Broadway Avenue
城市MINNEAPOLIS
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编55445
电话17634162850
网址https://www.cvrx.com/
公司代码CVRX
上市日期Jun 30, 2021
CEOHykes (Kevin)

CVRx Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Kevin Hykes
Mr. Kevin Hykes
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.00K
+16.67%
Mr. Joseph P. (Joe) Slattery, CPA
Mr. Joseph P. (Joe) Slattery, CPA
Lead Independent Director
Lead Independent Director
30.64K
--
Mr. Paul Verrastro
Mr. Paul Verrastro
Chief Marketing and Strategy Officer
Chief Marketing and Strategy Officer
16.84K
+1916.17%
Mr. Brent Binkowski
Mr. Brent Binkowski
Chief Operating Officer
Chief Operating Officer
16.60K
--
Mr. Jared Oasheim
Mr. Jared Oasheim
Chief Financial Officer
Chief Financial Officer
15.45K
-58.75%
Ms. Martha Shadan
Ms. Martha Shadan
Independent Director
Independent Director
--
--
Dr. Mudit K. Jain, Ph.D.
Dr. Mudit K. Jain, Ph.D.
Independent Director
Independent Director
--
--
Dr. Philip B. Adamson
Dr. Philip B. Adamson
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Kevin Ballinger
Mr. Kevin Ballinger
Independent Director
Independent Director
--
--
Mr. Kirk Nielsen
Mr. Kirk Nielsen
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Kevin Hykes
Mr. Kevin Hykes
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.00K
+16.67%
Mr. Joseph P. (Joe) Slattery, CPA
Mr. Joseph P. (Joe) Slattery, CPA
Lead Independent Director
Lead Independent Director
30.64K
--
Mr. Paul Verrastro
Mr. Paul Verrastro
Chief Marketing and Strategy Officer
Chief Marketing and Strategy Officer
16.84K
+1916.17%
Mr. Brent Binkowski
Mr. Brent Binkowski
Chief Operating Officer
Chief Operating Officer
16.60K
--
Mr. Jared Oasheim
Mr. Jared Oasheim
Chief Financial Officer
Chief Financial Officer
15.45K
-58.75%
Ms. Martha Shadan
Ms. Martha Shadan
Independent Director
Independent Director
--
--

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
由于公司未披露,未能获取相关数据
地区USD
名称
营收
占比
US
12.24M
90.09%
Others
1.35M
9.91%
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
Johnson & Johnson Innovation-JJDC, Inc.
15.42%
New Enterprise Associates (NEA)
7.73%
Vensana Capital Management LLC
6.53%
Gilde Equity Management Benelux B.V.
4.69%
The Vanguard Group, Inc.
4.16%
其他
61.47%
持股股东
持股股东
占比
Johnson & Johnson Innovation-JJDC, Inc.
15.42%
New Enterprise Associates (NEA)
7.73%
Vensana Capital Management LLC
6.53%
Gilde Equity Management Benelux B.V.
4.69%
The Vanguard Group, Inc.
4.16%
其他
61.47%
股东类型
持股股东
占比
Venture Capital
29.68%
Investment Advisor
11.15%
Hedge Fund
9.28%
Investment Advisor/Hedge Fund
5.96%
Private Equity
4.69%
Individual Investor
4.33%
Research Firm
3.62%
Pension Fund
0.42%
Bank and Trust
0.14%
其他
30.72%

机构持股

更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
228
17.05M
80.90%
-52.59K
2025Q3
232
17.10M
82.20%
-620.32K
2025Q2
227
17.72M
82.14%
-1.50M
2025Q1
219
19.22M
81.40%
-1.99M
2024Q4
217
18.52M
88.19%
+738.46K
2024Q3
205
17.48M
85.56%
+1.01M
2024Q2
202
16.95M
94.67%
-325.79K
2024Q1
200
17.25M
89.54%
-2.08M
2023Q4
194
16.01M
92.75%
+1.64M
2023Q3
187
14.37M
98.58%
+302.86K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Johnson & Johnson Innovation-JJDC, Inc.
4.10M
15.69%
--
--
Jun 30, 2025
New Enterprise Associates (NEA)
2.03M
7.75%
--
--
Jun 30, 2025
Vensana Capital Management LLC
1.71M
6.54%
--
--
Dec 31, 2024
Gilde Equity Management Benelux B.V.
1.23M
4.7%
-136.72K
-10.01%
Feb 04, 2025
The Vanguard Group, Inc.
1.08M
4.12%
+70.56K
+7.01%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
949.05K
3.63%
+27.13K
+2.94%
Jun 30, 2025
Jain (Mudit Kumar)
938.43K
3.59%
+1.65K
+0.18%
May 13, 2025
Balyasny Asset Management LP
674.68K
2.58%
+267.06K
+65.52%
Jun 30, 2025
Parkman Healthcare Partners LLC
789.10K
3.02%
-440.42K
-35.82%
Jun 30, 2025
Morgan Stanley & Co. LLC
347.67K
1.33%
+158.18K
+83.48%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0.03%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
JPMorgan Fundamental Data Science Small Core ETF
0%
iShares Russell 2000 Value ETF
0%
Avantis US Small Cap Equity ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
查看更多
iShares Micro-Cap ETF
占比0.03%
Proshares Ultra Russell 2000
占比0.01%
ProShares UltraPro Russell2000
占比0.01%
iShares Russell 2000 Growth ETF
占比0.01%
Global X Russell 2000 ETF
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
JPMorgan Fundamental Data Science Small Core ETF
占比0%
iShares Russell 2000 Value ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

CVRx Inc的前五大股东是谁?

CVRx Inc 的前五大股东如下:
Johnson & Johnson Innovation-JJDC, Inc.持有股份:4.10M,占总股份比例:15.69%。
New Enterprise Associates (NEA)持有股份:2.03M,占总股份比例:7.75%。
Vensana Capital Management LLC持有股份:1.71M,占总股份比例:6.54%。
Gilde Equity Management Benelux B.V.持有股份:1.23M,占总股份比例:4.70%。
The Vanguard Group, Inc.持有股份:1.08M,占总股份比例:4.12%。

CVRx Inc的前三大股东类型是什么?

CVRx Inc 的前三大股东类型分别是:
Johnson & Johnson Innovation-JJDC, Inc.
New Enterprise Associates (NEA)
Vensana Capital Management LLC

有多少机构持有CVRx Inc(CVRX)的股份?

截至2025Q4,共有228家机构持有CVRx Inc的股份,合计持有的股份价值约为17.05M,占公司总股份的80.90%。与2025Q3相比,机构持股有所增加,增幅为-1.30%。

哪个业务部门对CVRx Inc的收入贡献最大?

在FY2025Q2,--业务部门对CVRx Inc的收入贡献最大,创收--,占总收入的--%。
KeyAI